R. A. Huddart Et Al. , "PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)," Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , vol.38, San-Francisco, Costa Rica, 2020
Huddart, R. A. Et Al. 2020. PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC). Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , (San-Francisco, Costa Rica).
Huddart, R. A., Siefker-Radtke, A. O., Balar, A. V., Bilen, M. A., Powles, T., Bamias, A., ... Castellano, D.(2020). PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) . Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica
Huddart, Robert Et Al. "PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)," Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 2020
Huddart, Robert A. Et Al. "PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)." Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , San-Francisco, Costa Rica, 2020
Huddart, R. A. Et Al. (2020) . "PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)." Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={Robert A. Huddart Et Al. }, title={PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)}, congress name={Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)}, city={San-Francisco}, country={Costa Rica}, year={2020}}